title: Stage 1 Type 3 Neovascularization With Choroidal Dilation Unresponsive to Anti-VEGF Treatment.
abstract: Type 3 neovascularization is considered to originate within the retina with subsequent expansion of the neovascular network into the subretinal space. Choroidal circulatory disturbances seem to have a role in Type 3 neovascularization development, but the exact pathophysiology is still under debate. Although eyes with Type 3 neovascularization usually have thinner choroid compared to normal eyes, the increased choroidal thickness associated with Type 3 neovascularization may be a prognostic factor for its recurrence. This case report documents stage 1 Type 3 neovascularization with dilated choroid showing poor response to anti-vascular endothelial growth factor therapy, thus suggesting an active role of choroid in Type 3 lesions. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:956-959.].
authors.forename: Stela
authors.initials: S
authors.lastname: Vujosevic
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Martini
authors.forename: Edoardo
authors.initials: E
authors.lastname: Midena
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use*; D002829:Choroid / Q000098:blood supply* / Q000000981:diagnostic imaging; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D004108:Dilatation, Pathologic; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D041623:Tomography, Optical Coherence; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab